The rapid emergence of resistance
against frontline antimalarial
drugs essentially warrants the identification of new-generation antimalarials.
Here, we describe the synthesis of (<i>E</i>)-2-isopropyl-5-methyl-4-((2-(pyridin-4-yl)hydrazono)methyl)phenol
(<b>18</b>), which binds ferriprotoporphyrin-IX (Fe<sup>III</sup>-PPIX) (<i>K</i><sub>d</sub> = 33 nM) and offers antimalarial
activity against chloroquine-resistant and sensitive strains of <i>Plasmodium falciparum</i> in vitro. Structure–function
analysis reveals that compound <b>18</b> binds Fe<sup>III</sup>-PPIX through the −CN–NH– moiety and
2-pyridyl substitution at the hydrazine counterpart plays a critical
role in antimalarial efficacy. Live cell confocal imaging using a
fluorophore-tagged compound confirms its accumulation inside the acidic
food vacuole (FV) of <i>P. falciparum</i>. Furthermore,
this compound concentration-dependently elevates the pH in FV, implicating
a plausible interference with Fe<sup>III</sup>-PPIX crystallization
(hemozoin formation) by a dual function: increasing the pH and binding
free Fe<sup>III</sup>-PPIX. Different off-target bioassays reduce
the possibility of the promiscuous nature of compound <b>18</b>. Compound <b>18</b> also exhibits potent in vivo antimalarial
activity against chloroquine-resistant <i>P. yoelii</i> and <i>P. berghei</i> ANKA (causing cerebral malaria) in mice with
negligible toxicity.